Chemical and MaterialsHealthcareNewsPharmaceuticalTechnology

Global Hypoparathyroidism Drug Market growth of 8.1% CAGR forecast period 2019-2026 | Merck KGaA (Germany), GlaxoSmithKline Plc (UK), Takeda Pharmaceutical Company Limited (Japan),  Sun Pharmaceutical Industries Ltd (India), TESARO, Inc.(US)

Global Hypoparathyroidism Drug Market

Hypoparathyroidism Drug Market research report incorporates a significant synopsis of the key parts and the portions both rapidly and gradually developing divisions of the market. Global hypoparathyroidism drug market growth of 8.1% CAGR in the forecast period of 2019-2026, The market size, share of the market, and every segment based on various factors and sub-portion has been inspected through this examination.

Market Analysis: Global Hypoparathyroidism Drug Market

Global hypoparathyroidism drug market is expected to grow at a substantial growth of 8.1% CAGR in the forecast period of 2019-2026.

Key Market Players:

Few of the major competitors currently working in the hypoparathyroidism drug market are-Teva Pharmaceutical Industries Ltd (Israel), EnteraBio Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland),  Pfizer Inc. (US), Merck KGaA (Germany), GlaxoSmithKline Plc (UK), Takeda Pharmaceutical Company Limited (Japan),  Sun Pharmaceutical Industries Ltd (India), TESARO, Inc.(US), Amgen, Inc. (US), Ascendis Pharma A/S (Denmark) and among others.

FREE | Get a Copy of Sample Report Now! @

Market Definition:

Hypoparathyroidism is a rare disorder in which parathyroid glands present in the neck produce insufficient parathyroid hormone. Parathyroid hormone is responsible for regulating and maintaining of the balance of calcium and phosphate level. Hypoparathyroidism is characterized by low level of calcium and high level of phosphate in the blood. The patient with hypoparathyroidism may experience muscle cramps in legs or face, fatigue, painful mensuration, dry and coarse skin and paresthesia around fingertips and toes.

According to the published article in Journal of Rare Disorders Diagnosis & Therapy in 2018, it is estimated that 60 to 115,000 patients diagnosed with hypoparathyroidism in United States and approximately 37 per 100,000 patients with hypoparathyroidism new cases has seen per year. This significant rise in patient number acts as a driver for the market growth.

FREE | Request For TOC@

Segmentation: Global Hypoparathyroidism Drug Market

By Type

  • Iatrogenic Hypoparathyroidism
  • Idiopathic hypoparathyroidism
  • Inherited Genetic Hypoparathyroidism
  • Pseudo-hypoparathyroidism
  • Autoimmune Hypoparathyroidism
  • Others

By Drug Type

  • Vitamin D
  • Parathyroid Hormone
  • Tricalcium Phosphate
  • Calcium Lactate
  • Liothyronine
  • Etelcalcetide
  • Levothyroxine
  • Desiccated thyroid
  • Others

By Treatment

  • Medication
  • Hormone therapy
  • Dietary Supplements
  • Surgery

By Route of administration

  • Oral
  • Injectable

By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Market Restraints:

  • High cost involved in the treatment
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market
  • Lack of awareness among the patient and physician about Hypoparathyroidism treatment

Key Developments in the Market:

In February 2017, Amgen, Inc. received the FDA approval Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) who have been on hemodialysis. Parsabiv is a novel calcimimetic agent which is given intravenously by the dialysis specialist at the end of hemodialysis session.

In June 2018, Ascendis Pharma A/S received the FDA Orphan Drug Designation for TransCon PTH for the treatment of TransCon PTH is a long acting parathyroid hormone replacement therapy which helps in restoring the activity of parathyroid hormone.

FREE | Inquiry Before Buying and Discuss Report Customization with Industry Expert @

Competitive Analysis:

Global hypoparathyroidism drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hypoparathyroidism drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

  • Current and future of global hypoparathyroidism drug market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

FREE | Speak to Analyst and Get Free Customized Information about Report @

Potential of the report  :

  • Key developments and product launches in the market
  • To get a comprehensive overview of the Global Hypoparathyroidism Drug Market.
  • Key parameters which are driving the market
  • Strategies of key players and product offerings
  • In-depth market segmentation

 About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us-

Data Bridge Market Research

US: +1-888-387-2818



Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *